NCT00393484 - A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

September 30, 2013

Conditions

Chronic Hepatitis B

Interventions

DRUG

Entecavir

Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)

DRUG

Lamivudine Placebo

Capsules, Oral, 0 mg, once daily (0-96 weeks)

DRUG

Lamivudine

"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"

DRUG

Entecavir Placebo

Tablets, Oral, 0 mg, once daily (0-96 weeks)

Trial Locations (15)

420-717

Local Institution, Bucheon-si

602-739

Local Institution, Busan

200-704

Local Institution, Chuncheon

700-721

Local Institution, Daegu

705-030

Local Institution, Daegu

301-721

Local Institution, Daejeon

471-020

Local Institution, Guri-si

561-180

Local Institution, Jeonju

130-702

Local Institution, Seoul

135-270

Local Institution, Seoul

135-710

Local Institution, Seoul

136-705

Local Institution, Seoul

138-040

Local Institution, Seoul

150-950

Local Institution, Seoul

152-050

Local Institution, Seoul